Key points are not available for this paper at this time.
To identify predictors of discontinuing treatment with teriparatide (TPTD) and alendronate (ALN), data from a randomized, controlled trial (JOINT-05) involving postmenopausal Japanese women at high risk of fracture were re-analyzed.
Takeuchi et al. (Wed,) studied this question.